{"url_path":"/sec/rajaf/10-k/2026/item-7","section_key":"item-7","section_title":"Item 7 Major Shareholders and Related Party Transactions**","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1885680/0001213900-26-057774-index.html","accession_number":"0001213900-26-057774","cik":"0001885680","ticker":"RAJAF","issuer_name":"Cordyceps Sunshine Biotech Holdings Co., Ltd.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1885680/0001213900-26-057774-index.html","primary_entity_key":"0001885680","primary_entity_name":"Cordyceps Sunshine Biotech Holdings Co., Ltd."},"word_count":206,"has_tables":true,"body_markdown":"**Item\n7. Major Shareholders and Related Party Transactions**\n\n \n\n**7.A. Major Shareholders**\n\n \n\nPlease refer to “Item 6. Directors, Senior\nManagement and Employees - 6.E. Share Ownership.”\n\n** **\n\n**7.B. Related Party Transactions**\n\n \n\n**Terms of Directors\nand Officers**\n\n \n\nSee “Item 6. Directors,\nSenior Management and Employees-6.C. Board Practices-Terms of Directors and Officers.”\n\n** **\n\n**Employment Agreements\nand Indemnification Agreements**\n\n \n\nSee “Item 6. Directors,\nSenior Management and Employees-6.B. Compensation-Employment Agreements.”\n\n \n\n**Other Related Party\nTransactions**\n\n \n\nThe Company had transactions\nwith the following related parties:\n\n \n\n**Name of Related Party**\n \n**Nature of Relationship**\n\nMr. Szu Hao Huang\n \nDirector, Chief Executive Officer (“CEO”)\n\nMr. Yenhung Liu\n \nDirector of the Company\n\nChengdu Zhonghe sunshine Biotechnology Co., Ltd (“Chengdu Zhonghe”)\n \nA company whose legal representative is Mr. Yenhung Liu\n\nGasar Biotechnology Co., Ltd\n \nA company managed by Mr. Szu Hao Huang\n\nDalan Vincent Holdings Limited\n \nA company managed by Mr. Szu Hao Huang\n\n \n\n(1)\nDue to related parties\n\n \n\n  \nDecember 31,  \nDecember 31, \n\n  \n2025  \n2024 \n\nMr. Szu Hao Huang \n$140,140  \n$119,889 \n\nDalan Vincent Holdings Limited \n 99,975  \n 99,975 \n\nTotal \n$240,115  \n$219,864 \n\n \n\nThe amounts of due to related parties described\nabove were for working capital purposes, payable on demand, and bear no interest.\n\n \n\n(2)\nSales to related parties\n\n \n\n  \nYear Ended December 31, \n\n** **** **\n**2025**** **** **\n**2024**** **** **\n**2023**** **\n\nGasar Biotechnology Co., Ltd. \n$175,405  \n$52,943  \n$126,856"}